Richards Group (RIC) Q4 2025 earnings summary

Executive summary

• Fiscal 2025 was a transition year, marked by a strategic shift from dividend focus to growth, significant M&A activity, and investments in people, processes, and systems.

• The company now operates under two main segments: healthcare and packaging, with healthcare becoming the larger revenue contributor.

• Three major acquisitions—National Dental, Dermapen World, and WorldPRP—expanded the healthcare portfolio and global reach.

• A new long-term strategy extends to 2030, introducing 'globalize' and 'optimize' phases to drive international expansion and operational efficiency.

Financial highlights

• Revenue increased 5.5% year-over-year, driven by healthcare acquisitions, offset by declines in organic healthcare and food/beverage.

• Adjusted EBITDA margin declined to 13% of revenue, down 1% from the previous year, due to higher people costs and operating expenses from acquisitions.

• Q4 revenue accelerated by 5.8% over prior year; gross margins rose to 44.4% with healthcare acquisitions.

• Adjusted free cash flow decreased by CAD 4.6 million to CAD 34.9 million, impacted by higher interest and maintenance capital expenditures.

Outlook and guidance

• The company is shifting focus to profitable growth and high cash flow, with continued investment in digital, e-commerce, and international expansion.

• The long-term plan includes expanding OEM brands globally and optimizing real estate and organizational structure by 2030.